Scarica l'app Stockscreener
0.9706
4.68%
0.0434
Dopo l'orario di chiusura:
.97
-0.0006
-0.06%
Precedente Chiudi:
$0.9272
Aprire:
$0.94
Volume 24 ore:
235.06K
Relative Volume:
1.88
Capitalizzazione di mercato:
$14.69M
Reddito:
$3,000
Utile/perdita netta:
$-7.78M
Rapporto P/E:
-0.9381
EPS:
-1.0346
Flusso di cassa netto:
$-7.49M
1 W Prestazione:
-8.43%
1M Prestazione:
-21.09%
6M Prestazione:
-18.44%
1 anno Prestazione:
-37.78%
Intervallo 1D:
$0.87
$0.9706
Intervallo di 1 settimana:
$0.87
$1.08
Portata 52W:
$0.75
$1.80
Biocardia Inc Stock (BCDA) Company Profile
Nome
Biocardia Inc
Settore
Industria
Telefono
650-226-0123
Indirizzo
320 SOQUEL WAY, SUNNYVALE, CA
Compare BCDA vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BCDA
Biocardia Inc
|
0.9706 | 14.69M | 3,000 | -7.78M | -7.49M | -1.0346 |
VRTX
Vertex Pharmaceuticals Inc
|
508.74 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.35 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.50 | 53.23B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.30 | 42.34B | 5.76B | 514.49M | 1.10B | 4.4813 |
Biocardia Inc Stock (BCDA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-04-16 | Downgrade | Dawson James | Buy → Neutral |
Biocardia Inc Borsa (BCDA) Ultime notizie
BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting - GlobeNewswire Inc.
BioCardia president and CEO Peter Altman buys $1,030 in shares - Investing.com
At $1.03 a share, BioCardia (BCDA) CEO Peter Altman buys 1,000 shares. - Stock Titan
BioCardia CEO Peter Altman buys $1,995 in stock By Investing.com - Investing.com Canada
BioCardia CEO Peter Altman buys $1,995 in stock - Investing.com
BioCardia (BCDA) CEO buys shares at an average $1.05 each, bringing his direct holdings to 383,885. - Stock Titan
BioCardia Shares Fall 10% After Hours: Here's Why - Benzinga
BioCardia Shares Fall 10% After Hours: Here's Why - TradingView
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com Canada
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com India
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com UK
BioCardia to Present CardiAMP, Helix and Heart3D Progress at H.C. Wainwright Global Investment Conference - Quiver Quantitative
BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference - The Manila Times
BioCardia to present CardiAMP regulatory progress, Helix and Heart3D updates at H.C. Wainwright - TradingView
A heart-failure cell therapy could reach Japanese regulators by year-end. BioCardia is preparing the filing. - Stock Titan
Form 8K Biocardia Inc For: 10 September By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys 800 shares for $872 - Bitget
BioCardia CEO Peter Altman buys $872 in company stock By Investing.com - Investing.com Nigeria
BioCardia CEO Peter Altman buys $872 in company stock - Investing.com
BioCardia CEO Peter Altman buys $872 in company stock By Investing.com - Investing.com South Africa
BioCardia CEO Peter Altman buys $872 in company stock - Investing.com
BioCardia (BCDA) CEO adds 800 shares in open-market buy - Stock Titan
BioCardia Inc. Warrant (BCDAW) Key Financial Ratios – Valuation, Profitability & More - Value Research
BioCardia (BCDA) Session: Finishes 4.95% Higher at $1.06 at the Close; Price Setup: Price Remains Between $1.01 Support and $1.11 Resistance on the DaySmart Beta Flow - vinanet.vn
BioCardia receives FDA confirmation on Helix catheter meeting By Investing.com - Investing.com Nigeria
BioCardia Advances Helix Catheter Toward De Novo Approval - TipRanks
BioCardia receives FDA confirmation on Helix catheter meeting By Investing.com - Investing.com India
BioCardia (BCDA) Session: Finishes 4.95% Higher at $1.06 at the Close; Price Setup: Price Remains Between $1.01 Support and $1.11 Resistance on the DayDonchian Channel - dars.gov.et
BioCardia Receives Nasdaq Notice on Minimum Bid Price - The Globe and Mail
BioCardia Received Notice of Noncompliance - TradingView
BioCardia’s Q2 2026 Update Keeps the Regulatory Story Alive, but Capital Still Drives the Risk - AlphaStreet
BioCardia CEO Peter Altman acquires 5,400 common shares worth $5,022 - Bitget
BioCardia CEO Peter Altman buys $5,022 in company stock - Investing.com
BioCardia CEO Peter Altman buys $5,022 in company stock - Investing.com
BioCardia (BCDA) CEO buys 5,400 shares in open market - Stock Titan
BCDA Q2 2026 Earnings: EPS Surprise of 29.19% Narrows Losses as Shares Climb 4.82%Estimate Revision Count - vinanet.vn
BioCardia (BCDA) Pushes Higher: Micro-Cap Biotech Gains 4.8% as It Nears $1.02 ResistanceIceberg Order - vinanet.vn
BioCardia (BCDA) Pushes Higher: Micro-Cap Biotech Gains 4.8% as It Nears $1.02 ResistanceValue Area High - dars.gov.et
BCDA Q2 2026 Earnings: Narrower-than-Expected Loss Drives Shares Up 4.82%Earnings Revision Upgrade - vinanet.vn
Why Did BCDA Stock Surge More Than 50% Today? - Stocktwits
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com Canada
BioCardia CEO Peter Altman buys $1,748 in company stock - Investing.com
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com India
BioCardia CEO Peter Altman buys $1,748 in company stock By Investing.com - Investing.com UK
BioCardia (BCDA) CEO Peter Altman purchases 1,900 shares at $0.92 average price - Stock Titan
BioCardia (BCDA) Holds at $0.88 as Range-Bound Trading PersistsTriple Top - vinanet.vn
BioCardia (BCDA) Drops 5.6% to $0.88 as Micro-Cap Biotech Tests Support LevelInsider Buying Alerts - vinanet.vn
BioCardia (BCDA) Advances Regulatory Pathway, Faces High Price-t - GuruFocus
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulatory Wins in Japan and US ... - Yahoo! Finance Canada
BioCardia Inc (BCDA) (Q2 2026) Earnings Call Highlights: Regulat - GuruFocus
Biocardia Inc Azioni (BCDA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Biocardia Inc Azioni (BCDA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Altman Peter | President and CEO |
Sep 23 '26 |
Buy |
1.05 |
1,900 |
1,995 |
383,885 |
| Altman Peter | President and CEO |
Sep 03 '26 |
Buy |
1.09 |
800 |
872 |
381,985 |
| Altman Peter | President and CEO |
Aug 17 '26 |
Buy |
0.93 |
5,400 |
5,022 |
381,115 |
| Altman Peter | President and CEO |
Aug 13 '26 |
Buy |
0.92 |
1,900 |
1,748 |
375,785 |
| Altman Peter | President and CEO |
Jul 29 '26 |
Buy |
0.78 |
5,000 |
3,900 |
373,885 |
| Altman Peter | President and CEO |
Jul 17 '26 |
Buy |
0.83 |
500 |
415 |
368,885 |
| Altman Peter | President and CEO |
Jul 15 '26 |
Buy |
0.86 |
1,500 |
1,290 |
368,385 |
| Altman Peter | President and CEO |
Jul 14 '26 |
Buy |
0.88 |
2,800 |
2,464 |
366,885 |
| Altman Peter | President and CEO |
Jul 10 '26 |
Buy |
0.94 |
1,000 |
940 |
369,485 |
| Altman Peter | President and CEO |
Jul 09 '26 |
Buy |
0.90 |
1,000 |
900 |
368,485 |
1.49%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):